$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
How long does it take to see obvious effects after taking Upatinib/Refu, and what are the rules?
2026-02-01 22:25:32
Check Details
Precautions when using bimetinib/bemetinib
2026-02-01 22:25:32
Check Details
Storage conditions and precautions for Teritusumab/Telivac
2026-02-01 22:25:32
Check Details
Quizartinib therapeutic targets and mechanisms of action
2026-02-01 22:25:32
Check Details
What is the proportion of pomalidomide reimbursed by medical insurance?
2026-02-01 22:25:32
Check Details
Dosage of subcutaneous injection of evantumumab (Rybrevant Faspro)
2026-02-01 22:25:32
Check Details
What are the drug interactions of selumetinib/coceyu?
2026-02-01 22:25:32
Check Details
How is the research progress of lorlatinib/lorlatinib related to ROS1?
2026-02-01 22:25:32
Check Details
What are the contraindications for Cabozantinib?
2026-02-01 22:25:32
Check Details
Introduction to Bosutinib Overview
2026-02-01 22:25:32
Check Details
What is the mechanism of action of nintedanib/Vigat and how it affects the efficacy
2026-02-01 22:25:32
Check Details
FDA approves evantuzumab injection (Rybrevant Faspro) for subcutaneous treatment of non-small cell lung cancer
2026-02-01 22:25:32
Check Details
1
2
...
2394
2395
2396
2397
2398
2399
2400
...
2441
2442
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Juvmo (tavapadon) for Adult Parkinson’s: D1/D5 Partial Agonist, Once Daily, Monotherapy or Adjunct to Levodopa
2
Emcitate (tiratricol) for MCT8 Deficiency Peripheral Thyrotoxicosis: Bypass MCT8, Lower T3, Monitor Heart Rate and Bone
3
Lyrfigtu (lirafugratinib) for Pretreated FGFR2 Cholangiocarcinoma: 70mg Daily, REFOCUS Efficacy, Ocular and Phosphate Monitoring
4
Fayuvi (rebisufligene etisparvovec-hopf/UX111) for MPS IIIA: AAV9 SGSH Gene Therapy, Cognition, and Safety
5
Ramosetron Hydrochloride Orally Disintegrating Tablets: A 5-HT3 Receptor Antagonist for Diarrhea-Predominant IBS
6
Pixclara (Floretyrosine F-18/18F-FET) Glioma PET: Distinguishing Recurrence from Treatment-Related Change
7
Bexlutry (Lu-177 Dotatate) for SSTR-Positive GEP-NETs: PRRT Dosing and Safety Monitoring
8
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
9
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
10
Mirogabalin for Neuropathic Pain: Onset Time and Dosing Strategy
11
Zanvastro (zilganersen-alexander) Intrathecal Injection: First Targeted Therapy for Alexander Disease
12
FDA Approves LISRAYA (brepocitinib): First Oral Targeted Therapy for Adults with Dermatomyositis